肝纖維化是各種慢性肝病進(jìn)展到肝硬化必經(jīng)的階段，早期抑制肝纖維化的發(fā)生發(fā)展在肝病治療中至關(guān)重要。細(xì)胞死亡在肝纖維化的發(fā)生機(jī)制中作用復(fù)雜，但是卻是肝纖維化治療的潛在靶點(diǎn)，近年來(lái)，關(guān)于各種中藥單體及中藥復(fù)方通過(guò)調(diào)控細(xì)胞死亡治療肝纖維化的研究層出不窮。基于此，通過(guò)匯總最新國(guó)內(nèi)外相關(guān)文獻(xiàn)，以中藥活性成分及中藥復(fù)方為重點(diǎn)，以細(xì)胞死亡調(diào)控方式為出發(fā)點(diǎn)，對(duì)肝纖維化的治療進(jìn)行綜述，為肝纖維化的臨床治療提供參考。

Liver fibrosis is an inevitable stage in the progression of various chronic liver diseases to cirrhosis, and early inhibition of liver fibrosis is crucial in the treatment of liver diseases. Cell death plays a complex role in the mechanism of liver fibrosis, but it is a potential target for treatment of liver fibrosis. In recent years, there have been numerous studies on treatment of liver fibrosis by modulating cell death through various Chinese medicinal monomers and traditional Chinese medicinal combinations. Based on this, by summarizing the latest domestic and international literature and taking cell death modulation as the starting point, the treatment of liver fibrosis by focusing on the active ingredients of traditional Chinese medicines and traditional Chinese medicinal compounds was reviewed, with view to providing reference for the clinical treatment of liver fibrosis.

R285

國(guó)家自然科學(xué)基金面上項(xiàng)目（82274323）